GlassScriptPhysician profile
Jayaram B Naidu
NPI 1710954292
$5,547.01
in general payments reported to CMS, 2019-2025
38 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,084 · 2020: $638 · 2021: $1,262 · 2022: $1,094 · 2023: $696 · 2024: $412 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,389 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,389.23 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $851.57 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $640.67 | 2019-2025 | Breztri, Farxiga, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $443.24 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $410.41 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $382.33 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $379.81 | 2019-2024 | Tavneos, Repatha, Otezla |
| Abbott Laboratories | $277.66 | 2022-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $228.80 | 2019-2025 | Wegovy |
| Medtronic, INC. | $167.14 | 2021-2025 | Minimed 780g |
| Pfizer INC. | $145.32 | 2020-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.63 | 2021-2024 | Xifaxan |
| Travere Therapeutics, INC. | $125.00 | 2025 | Filspari |
| Abbvie INC. | $120.50 | 2021-2022 | |
| Astellas Pharma US INC | $115.46 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $101.17 | 2022-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $90.98 | 2019-2022 | |
| Genzyme Corporation | $90.00 | 2019 | |
| Mylan Specialty L.P. | $79.59 | 2019-2021 | |
| Boston Scientific Corporation | $74.84 | 2022-2023 | Wolverine Coronary Cutting Balloon |
| Janssen Pharmaceuticals, INC | $72.46 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $66.56 | 2019 | |
| Allergan, INC. | $66.06 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.40 | 2022-2024 | |
| Eisai INC. | $53.15 | 2020-2021 | |
| Medtronic Vascular, INC. | $46.86 | 2020 | |
| Amarin Pharma, INC. | $45.72 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $42.48 | 2021 | |
| Xeris Pharmaceuticals, INC. | $37.72 | 2024 | Gvoke Hypopen |
| Radius Health, INC. | $34.21 | 2019-2020 | |
| Grifols USA, LLC | $33.31 | 2019 | |
| Arbor Pharmaceuticals, INC. | $27.66 | 2022 | |
| Genentech USA, INC. | $26.09 | 2019 | |
| Dexcom, INC. | $20.98 | 2021 | |
| Melinta Therapeutics, LLC | $18.10 | 2019 | |
| Janssen Biotech, INC. | $17.78 | 2022 | |
| Insulet Corporation | $15.91 | 2022 | |
| Horizon Therapeutics Plc | $12.44 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayaram Naidu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.